Single-cycle rituximab-induced immunologic changes in children Enhanced in neuroimmunologic disease?
Open Access
- 5 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To investigate the immunologic impact of a single cycle of rituximab (RTX) in children and adolescents with immune-mediated disorders, we evaluated B cells and immunoglobulin levels of 20 patients with neuroimmunologic, nephrologic, dermatologic, and rheumatologic disorders treated under recommended guidelines. Methods Retrospective study of immunologic changes in children (aged <= 18 years) diagnosed with immune-mediated disorders in which RTX was prescribed between June 2014 and February 2019. Patients were excluded if they had prior diagnosis of malignant disease or primary immunodeficiency. Patients were clinically and immunologically followed up every 3 months. Only patients having received a single cycle of RTX and with a follow-up greater than 12 months were included in the analysis of persistent dysgammaglobulinemia. Results Twenty children were included. Median age at RTX treatment was 12.8 years (interquartile range [IQR] 6.6-15.5 years). Median follow-up was 12.6 months (IQR 10.2-24 months). Of the 14 patients eligible for persistent dysgammaglobulinemia analysis (3 had received RTX retreatment, 2 had <12 months post-RTX follow-up, and in 1 data for this time point was missing), 2/14 (14%) remained with complete B-cell depletion, and 5/14 (36%) had dysgammaglobulinemia. Patients with dysgammaglobulinemia were younger (7.8 vs 15.6 years,p= 0.072), had more underlying neuroimmunologic diseases (5/5 vs 0/9,p< 0.001), and had received more frequently concentrated doses of RTX (3/5 vs 1/9,p= 0.05) than patients without dysgammaglobulinemia. Kinetics of immunoglobulins in the 20 patients revealed a decrease as early as 3 months after RTX in patients with neuroimmunologic disorders. Conclusion In our cohort, single-cycle RTX-induced dysgammaglobulinemia was enhanced in patients with neuroimmunologic diseases. Further studies are needed to confirm this observation.This publication has 29 references indexed in Scilit:
- Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United KingdomRheumatology, 2018
- Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitutionImmunotherapy, 2018
- Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseasesPLOS ONE, 2018
- Risk factors predisposing to the development of hypogammaglobulinemia and infections post-RituximabInternational Reviews of Immunology, 2017
- Suppression of normal immune responses after treatment with rituximabCurrent Opinion in Rheumatology, 2016
- Development of immunity in early lifeJournal of Infection, 2015
- Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?Cancers, 2015
- Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United StatesThe Journal of Pediatrics, 2012
- Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignanciesCancer Treatment Reviews, 2012
- Tolerability and safety of rituximab (MabThera®)Cancer Treatment Reviews, 2005